Physician profile
Vincent Sciortino
NPI 1245290840
$26,344.95
in general payments reported to CMS, 2019-2025
55 companies · $2,939 in 2025
The $2,939 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,011 · 2020: $2,715 · 2021: $3,724 · 2022: $4,024 · 2023: $3,914 · 2024: $4,018 · 2025: $2,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,791.01 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,508.41 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $3,328.14 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,909.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $1,517.53 | 2019-2024 | Livalo, Seglentis, Zoryve |
| Amgen INC. | $1,366.84 | 2019-2025 | Otezla, Evenity, Repatha |
| Abbvie INC. | $1,298.13 | 2019-2025 | Ubrelvy, Qulipta, Mavyret |
| Pfizer INC. | $899.52 | 2019-2025 | |
| Radius Health, INC. | $839.19 | 2019-2023 | Tymlos |
| Astellas Pharma US INC | $829.99 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $807.20 | 2019-2023 | |
| Novo Nordisk INC | $703.46 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $618.20 | 2019-2023 | Keytruda, Verquvo, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $593.09 | 2019-2024 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $493.80 | 2019-2025 | |
| Janssen Biotech, INC. | $488.09 | 2020-2024 | Rybrevant |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Sciortino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.